Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report.

ABSTRACT

•Immune checkpoint inhibitors can be safely administered to patients with dermatomyositis.•Immunosuppressants did not impact the efficacy of treatment with an immune check point inhibitor.•Patients with autoimmune disorders who require immune check point inhibitors should be monitored by a rheumatologist.